Entera Bio Ltd
ENTX1.770USD
-0.170-8.76%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
80.83MMarket Cap
LossP/E TTM
More Details of Entera Bio Ltd Company
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Entera Bio Ltd Info
Ticker SymbolENTX
Company nameEntera Bio Ltd
IPO dateJun 28, 2018
CEOToledano (Miranda Jayne)
Number of employees18
Security typeOrdinary Share
Fiscal year-endJun 28
AddressHadassah / Jerusalem Bio
CityJERUSALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code9112002
Phone97225327151
Websitehttps://enterabio.com/
Ticker SymbolENTX
IPO dateJun 28, 2018
CEOToledano (Miranda Jayne)
Company Executives of Entera Bio Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Independent Director
Independent Director
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Other
62.81%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Other
62.81%
Shareholder Types
Shareholders
Proportion
Corporation
21.80%
Hedge Fund
17.54%
Individual Investor
2.41%
Investment Advisor/Hedge Fund
1.41%
Investment Advisor
0.66%
Family Office
0.31%
Research Firm
0.11%
Venture Capital
0.02%
Other
55.74%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
31
10.02M
22.66%
--
2025Q3
32
10.02M
22.66%
-49.40K
2025Q2
33
10.07M
22.72%
-152.10K
2025Q1
34
10.22M
23.69%
-537.14K
2024Q4
32
7.49M
20.14%
+518.60K
2024Q3
30
5.32M
15.79%
+29.98K
2024Q2
29
5.29M
11.96%
+1.38M
2024Q1
26
4.27M
12.41%
-130.45K
2023Q4
26
4.07M
8.01%
+1.48M
2023Q3
27
2.59M
10.16%
+9.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.88M
12.88%
--
--
Jun 30, 2025
OPKO Health Inc
3.87M
8.46%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.17%
--
--
May 08, 2025
Centillion Fund Inc
2.40M
5.25%
--
--
May 08, 2025
Point72 Asset Management, L.P.
2.70M
5.91%
--
--
Jun 30, 2025
Schonfeld Strategic Advisors LLC
604.52K
1.32%
+5.37K
+0.90%
Jun 30, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
291.45K
0.64%
+180.70K
+163.16%
Jul 16, 2025
Parkman Healthcare Partners LLC
355.82K
0.78%
-83.81K
-19.06%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Entera Bio Ltd?
The top five shareholders of Entera Bio Ltd are:
Knoll Capital Management, LLC holds 5.88M shares, accounting for 12.88% of the total shares.
OPKO Health Inc holds 3.87M shares, accounting for 8.46% of the total shares.
D.N.A Biomedical Solutions, Ltd. holds 3.73M shares, accounting for 8.17% of the total shares.
Centillion Fund Inc holds 2.40M shares, accounting for 5.25% of the total shares.
Point72 Asset Management, L.P. holds 2.70M shares, accounting for 5.91% of the total shares.
Knoll Capital Management, LLC holds 5.88M shares, accounting for 12.88% of the total shares.
OPKO Health Inc holds 3.87M shares, accounting for 8.46% of the total shares.
D.N.A Biomedical Solutions, Ltd. holds 3.73M shares, accounting for 8.17% of the total shares.
Centillion Fund Inc holds 2.40M shares, accounting for 5.25% of the total shares.
Point72 Asset Management, L.P. holds 2.70M shares, accounting for 5.91% of the total shares.
What are the top three shareholder types of Entera Bio Ltd?
The top three shareholder types of Entera Bio Ltd are:
Knoll Capital Management, LLC
OPKO Health Inc
D.N.A Biomedical Solutions, Ltd.
Knoll Capital Management, LLC
OPKO Health Inc
D.N.A Biomedical Solutions, Ltd.
How many institutions hold shares of Entera Bio Ltd (ENTX)?
As of 2025Q4, 31 institutions hold shares of Entera Bio Ltd, with a combined market value of approximately 10.02M, accounting for 22.66% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Entera Bio Ltd?
In --, the -- business generated the highest revenue for Entera Bio Ltd, amounting to -- and accounting for --% of total revenue.
